vs
盖尔斯（GES）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
盖尔斯的季度营收约是Revvity的1.0倍（$791.4M vs $772.1M），Revvity净利率更高（12.7% vs 3.2%，领先9.5%），盖尔斯同比增速更快（7.2% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-56.3M），过去两年Revvity的营收复合增速更高（9.0% vs -5.8%）
盖尔斯是美国知名服饰品牌企业，以标志性的黑白风格广告广为人知。除核心服饰产品外，品牌还通过品牌授权模式推出腕表、珠宝、香水、包袋、鞋履等各类时尚配饰，在全球时尚消费市场拥有较高知名度。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GES vs RVTY — 直观对比
营收规模更大
GES
是对方的1.0倍
$772.1M
营收增速更快
GES
高出1.3%
5.9%
净利率更高
RVTY
高出9.5%
3.2%
自由现金流更多
RVTY
多$218.1M
$-56.3M
两年增速更快
RVTY
近两年复合增速
-5.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $791.4M | $772.1M |
| 净利润 | $25.6M | $98.4M |
| 毛利率 | 42.5% | — |
| 营业利润率 | 2.9% | 14.5% |
| 净利率 | 3.2% | 12.7% |
| 营收同比 | 7.2% | 5.9% |
| 净利润同比 | 209.6% | 3.9% |
| 每股收益（稀释后） | $0.48 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GESRVTY
| Q4 25 | $791.4M | $772.1M | ||
| Q3 25 | $772.9M | $698.9M | ||
| Q2 25 | $647.8M | $720.3M | ||
| Q1 25 | $932.3M | $664.8M | ||
| Q4 24 | $738.5M | $729.4M | ||
| Q3 24 | $732.6M | $684.0M | ||
| Q2 24 | $591.9M | $691.7M | ||
| Q1 24 | $891.0M | $649.9M |
净利润GESRVTY
| Q4 25 | $25.6M | $98.4M | ||
| Q3 25 | $6.2M | $46.7M | ||
| Q2 25 | $-32.9M | $53.9M | ||
| Q1 25 | $81.4M | $42.2M | ||
| Q4 24 | $-23.4M | $94.6M | ||
| Q3 24 | $-10.6M | $94.4M | ||
| Q2 24 | $13.0M | $55.4M | ||
| Q1 24 | $115.3M | $26.0M |
毛利率GESRVTY
| Q4 25 | 42.5% | — | ||
| Q3 25 | 42.5% | 53.6% | ||
| Q2 25 | 39.9% | 54.5% | ||
| Q1 25 | 44.1% | 56.5% | ||
| Q4 24 | 43.6% | — | ||
| Q3 24 | 43.7% | 56.3% | ||
| Q2 24 | 41.9% | 55.7% | ||
| Q1 24 | 45.4% | 54.6% |
营业利润率GESRVTY
| Q4 25 | 2.9% | 14.5% | ||
| Q3 25 | 2.3% | 11.7% | ||
| Q2 25 | -5.1% | 12.6% | ||
| Q1 25 | 11.1% | 10.9% | ||
| Q4 24 | 5.7% | 16.3% | ||
| Q3 24 | 6.5% | 14.3% | ||
| Q2 24 | -3.4% | 12.4% | ||
| Q1 24 | 16.3% | 6.8% |
净利率GESRVTY
| Q4 25 | 3.2% | 12.7% | ||
| Q3 25 | 0.8% | 6.7% | ||
| Q2 25 | -5.1% | 7.5% | ||
| Q1 25 | 8.7% | 6.4% | ||
| Q4 24 | -3.2% | 13.0% | ||
| Q3 24 | -1.4% | 13.8% | ||
| Q2 24 | 2.2% | 8.0% | ||
| Q1 24 | 12.9% | 4.0% |
每股收益（稀释后）GESRVTY
| Q4 25 | $0.48 | $0.86 | ||
| Q3 25 | $0.12 | $0.40 | ||
| Q2 25 | $-0.65 | $0.46 | ||
| Q1 25 | $1.29 | $0.35 | ||
| Q4 24 | $-0.47 | $0.77 | ||
| Q3 24 | $-0.28 | $0.77 | ||
| Q2 24 | $0.23 | $0.45 | ||
| Q1 24 | $1.90 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $154.2M | $919.9M |
| 总债务越低越好 | $299.5M | — |
| 股东权益账面价值 | $508.5M | $7.3B |
| 总资产 | $3.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.59× | — |
8季度趋势，按日历期对齐
现金及短期投资GESRVTY
| Q4 25 | $154.2M | $919.9M | ||
| Q3 25 | $189.6M | $931.4M | ||
| Q2 25 | $151.2M | $991.8M | ||
| Q1 25 | $187.7M | $1.1B | ||
| Q4 24 | $140.9M | $1.2B | ||
| Q3 24 | $218.9M | $1.2B | ||
| Q2 24 | $241.7M | $2.0B | ||
| Q1 24 | $360.3M | $1.7B |
总债务GESRVTY
| Q4 25 | $299.5M | — | ||
| Q3 25 | $258.4M | — | ||
| Q2 25 | $241.7M | — | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $238.3M | — | ||
| Q3 24 | $187.8M | — | ||
| Q2 24 | $196.9M | — | ||
| Q1 24 | $28.2M | — |
股东权益GESRVTY
| Q4 25 | $508.5M | $7.3B | ||
| Q3 25 | $487.6M | $7.4B | ||
| Q2 25 | $483.6M | $7.6B | ||
| Q1 25 | $505.0M | $7.6B | ||
| Q4 24 | $450.7M | $7.7B | ||
| Q3 24 | $491.2M | $7.9B | ||
| Q2 24 | $565.5M | $7.9B | ||
| Q1 24 | $684.9M | $7.8B |
总资产GESRVTY
| Q4 25 | $3.0B | $12.2B | ||
| Q3 25 | $3.0B | $12.1B | ||
| Q2 25 | $2.9B | $12.4B | ||
| Q1 25 | $2.8B | $12.4B | ||
| Q4 24 | $2.8B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.6B | $13.4B |
负债/权益比GESRVTY
| Q4 25 | 0.59× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-39.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-56.3M | $161.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 21.0% |
| 资本支出强度资本支出/营收 | 2.1% | 2.6% |
| 现金转化率经营现金流/净利润 | -1.54× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $62.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GESRVTY
| Q4 25 | $-39.5M | $182.0M | ||
| Q3 25 | $74.9M | $138.5M | ||
| Q2 25 | $-73.4M | $134.3M | ||
| Q1 25 | $183.2M | $128.2M | ||
| Q4 24 | $-83.3M | $174.2M | ||
| Q3 24 | $44.7M | $147.9M | ||
| Q2 24 | $-22.9M | $158.6M | ||
| Q1 24 | $289.5M | $147.6M |
自由现金流GESRVTY
| Q4 25 | $-56.3M | $161.8M | ||
| Q3 25 | $53.4M | $120.0M | ||
| Q2 25 | $-95.3M | $115.5M | ||
| Q1 25 | $160.7M | $112.2M | ||
| Q4 24 | $-105.4M | $149.8M | ||
| Q3 24 | $24.3M | $125.6M | ||
| Q2 24 | $-44.0M | $136.6M | ||
| Q1 24 | $267.8M | $129.7M |
自由现金流率GESRVTY
| Q4 25 | -7.1% | 21.0% | ||
| Q3 25 | 6.9% | 17.2% | ||
| Q2 25 | -14.7% | 16.0% | ||
| Q1 25 | 17.2% | 16.9% | ||
| Q4 24 | -14.3% | 20.5% | ||
| Q3 24 | 3.3% | 18.4% | ||
| Q2 24 | -7.4% | 19.7% | ||
| Q1 24 | 30.1% | 20.0% |
资本支出强度GESRVTY
| Q4 25 | 2.1% | 2.6% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 3.4% | 2.6% | ||
| Q1 25 | 2.4% | 2.4% | ||
| Q4 24 | 3.0% | 3.4% | ||
| Q3 24 | 2.8% | 3.3% | ||
| Q2 24 | 3.6% | 3.2% | ||
| Q1 24 | 2.4% | 2.7% |
现金转化率GESRVTY
| Q4 25 | -1.54× | 1.85× | ||
| Q3 25 | 12.00× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 2.25× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | -1.76× | 2.87× | ||
| Q1 24 | 2.51× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GES
| Products | $760.3M | 96% |
| Royalty | $31.1M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
